BOSTON, MA and HAMILTON, ONTARIO, April 27, 2018 – Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), announced it will present at the Bloom Burton & Co. Healthcare Investor Conference 2018 in Toronto, Canada. The Fusion team will also participate in one-on-one meetings with industry stakeholders during the conference.
Details of the presentation are as follows:
- Date: Thursday, May 3, 2018
- Time: 11:30am ET
- Location: Hall B, Sheraton Centre Toronto Hotel, Toronto, Canada
About the Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest development in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings.
About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01 with a clinical trial planned for 2018, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships. For more information, please visit www.fusionpharma.com or contact info@fusionpharma.com.
Contacts
Fusion Pharmaceuticals
Lynn Wick
info@fusionpharma.com
